ライフサイエンスコーパス: membranoproliferative

1 Histologic patterns were predominantly membranoproliferative (57%) or endocapillary proliferati

2 noninvolved portion of the kidney revealed a membranoproliferative glomerular lesion, a lesion usuall

3 d premature death due to rapidly progressing membranoproliferative glomerular nephritis.

4 athological diagnoses on renal biopsies were membranoproliferative glomerulonephritis (23%) followed

5 ciated with hemolytic uremic syndrome (HUS), membranoproliferative glomerulonephritis (dense deposit

6 (FSGS), 57; immunoglobulin A nephritis, 22; membranoproliferative glomerulonephritis (GN), 18; and m

7 We also evaluated the risk of membranoproliferative glomerulonephritis (MPGN) and cryo

8 Membranoproliferative glomerulonephritis (MPGN) is seen

9 Membranoproliferative glomerulonephritis (MPGN) occurs i

10 Membranoproliferative glomerulonephritis (MPGN) recently

11 opathies, such as IgA nephropathy (IgAN) and membranoproliferative glomerulonephritis (MPGN) remains

12 Membranoproliferative glomerulonephritis (MPGN) type II

13 , a model of cryoglobulinemia and associated membranoproliferative glomerulonephritis (MPGN), in whic

14 TSLPtg) mice, which develop cryoglobulinemic membranoproliferative glomerulonephritis (MPGN).

15 y progressive glomerulonephritis (RPGN), and membranoproliferative glomerulonephritis (MPGN).

16 as been associated with de novo or recurrent membranoproliferative glomerulonephritis and acute trans

17 d-stage renal disease in 12; one patient had membranoproliferative glomerulonephritis and another pat

18 een reported to be typically associated with membranoproliferative glomerulonephritis and less freque

19 This included membranoproliferative glomerulonephritis and relapses in

20 nty-one patients with biopsy-proven, diffuse membranoproliferative glomerulonephritis and significant

21 By 6 months of age, ABCA1-/- animals develop membranoproliferative glomerulonephritis due to depositi

22 malities in factor H have been implicated in membranoproliferative glomerulonephritis in both humans

23 ch was before the development of spontaneous membranoproliferative glomerulonephritis in some Cfh(-/-

24 in a mouse model of cryoglobulin-associated membranoproliferative glomerulonephritis induced by over

25 Membranoproliferative glomerulonephritis recurred in eig

26 ients had immune-complex glomerulonephritis: membranoproliferative glomerulonephritis type 1 (n = 12)

27 The predominant renal biopsy findings were membranoproliferative glomerulonephritis type 1 or type

28 ceased donor transplants were not present in membranoproliferative glomerulonephritis type I (adjuste

29 Membranoproliferative glomerulonephritis type I [24 of 2

30 reviously published studies of patients with membranoproliferative glomerulonephritis type I are smal

31 allograft for end-stage renal disease due to membranoproliferative glomerulonephritis type I is prese

32 Membranoproliferative glomerulonephritis type II (MPGN I

33 Membranoproliferative glomerulonephritis type II (MPGN I

34 ypical hemolytic uremic syndrome (aHUS), and membranoproliferative glomerulonephritis type II (MPGN2)

35 Dense deposit disease (DDD; also known as membranoproliferative glomerulonephritis type II) is a p

36 innate immunity, and CFH deficiency leads to membranoproliferative glomerulonephritis type II.

37 nephropathy to 2.09 (95% CI, 1.56-2.78) for membranoproliferative glomerulonephritis type II.

38 plant FSGS was 2.25 (1.6-3.1), P<0.0001, for membranoproliferative glomerulonephritis was 2.37 (1.3-4

39 Renal involvement usually manifests as a membranoproliferative glomerulonephritis with marked mon

40 enal (membranous glomerulonephritis [GN] and membranoproliferative glomerulonephritis); hematologic (

41 al was seen with recurrent and de novo FSGS, membranoproliferative glomerulonephritis, and HUS/TTP.

42 hey developed splenomegaly, lymphadenopathy, membranoproliferative glomerulonephritis, and lymphocyti

43 nephritides (e.g. Alport's Syndrome, type II membranoproliferative glomerulonephritis, and membranous

44 vere kidney disorders including mesangial or membranoproliferative glomerulonephritis, and/or Henoch

45 gy, whereas overexpression of TSLP induced a membranoproliferative glomerulonephritis, as previously

46 ulting from other glomerular diseases (FSGS, membranoproliferative glomerulonephritis, IgA nephropath

47 riably demonstrating severe neonatal anemia, membranoproliferative glomerulonephritis, liver fibrosis

48 tic nephropathy, membranous lupus nephritis, membranoproliferative glomerulonephritis, postinfectious

49 3 glomerulopathies/immune complex-associated membranoproliferative glomerulonephritis, serum-induced

50 on with hepatitis C virus (HCV) infection is membranoproliferative glomerulonephritis, with or withou

51 nemia and severe cryoglobulinemia-associated membranoproliferative glomerulonephritis.

52 recurrent bacterial infections and to type 1 membranoproliferative glomerulonephritis.

53 tis, IgA nephropathy, Alport's syndrome, and membranoproliferative glomerulonephritis.

54 ed with diseases such as IgA nephropathy and membranoproliferative glomerulonephritis.

55 Two patients developed membranoproliferative glomerulonephritis.

56 s nephropathy (HR, 0.88; 95% CI, 0.83-0.93), membranoproliferative GN (HR, 0.84; 95% CI, 0.76-0.92),

57 erulopathy (C3G) and immune complex-mediated membranoproliferative GN (IC-MPGN).

58 t of 141 patients with C3G and Ig-associated membranoproliferative GN (Ig-MPGN) for anti-FB and anti-

59 hropathy (DN), FSGS, IgA nephropathy (IgAN), membranoproliferative GN (MPGN) (n=19-23 for each diseas

60 Renal microangiopathies and membranoproliferative GN (MPGN) can manifest similar cli

61 Membranoproliferative GN (MPGN) was recently reclassifie

62 C3 activation is a characteristic finding in membranoproliferative GN (MPGN).

63 There was a greater prevalence of membranoproliferative GN among patients with HCV but not

64 immune complex GNs such as membranous GN and membranoproliferative GN are particularly common renal m

65 ngial proliferative GN in eight patients and membranoproliferative GN in six patients.

66 +/-eGFR was 39.5+/-20.4 ml/min per 1.73 m(2) Membranoproliferative GN was the predominant histologic

67 iated crescentic GN, lupus nephritis, type I membranoproliferative GN), and nephrotic syndrome (minim

68 , lichen planus, vitiligo, cryoglobulinemia, membranoproliferative GN, and NHL.

69 AN (referent), FSGS, membranous nephropathy, membranoproliferative GN, lupus nephritis, and vasculiti

70 A nephropathy and one specimen of sclerosing membranoproliferative GN, showed bright (2-3+) C4d stain

71 ort of 142 unrelated patients diagnosed with membranoproliferative GN.

72 ntified DGKE gene variants as the cause of a membranoproliferative-like glomerular microangiopathy.

73 Renal biopsy revealed a membranoproliferative pattern of glomerular disease in f

74 linemia, which enables detailed studies of a membranoproliferative pattern of glomerular injury.

75 way and frequently deviates from the classic membranoproliferative pattern of injury on light microsc

76 Renal involvement was of a membranoproliferative type demonstrating thickened capil